Consensus SLM Corporation

Equities

SLM

US78442P1066

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
21.79 USD +0.88% Intraday chart for SLM Corporation +0.79% +13.96%

Evolution of the average Target Price on SLM Corporation

Price target over the last 5 years

History of analyst recommendation changes

90.4RgyVtFx5XRgy1K1hbrhwns_bISr9Ctsn65tYZHvhmA.u3xfHKcrrywSgjHy64K5oA58Fdfsths2zcUvUveo1BSWaEQvtCSPAgyZMQ~0a67b3c7d95e46cce74a58ea307243dc
Morgan Stanley Lifts Price Target on SLM to $23 From $21, Keeps Overweight Rating MT
RBC Raises Price Target on SLM to $22 From $21, Calls Q4 Results 'Solid,' Keeps Outperform Rating MT
Citigroup Upgrades SLM to Buy From Neutral, Raises Price Target to $23 From $14 MT
Deutsche Bank Initiates SLM at Buy Rating With $25 Price target MT
RBC Boosts Price Target on SLM to $21 From $16, Keeps Outperform Rating MT
JPMorgan Downgrades SLM to Neutral From Overweight, Raises Price Target to $20 From $18 MT
Morgan Stanley Raises Price Target on SLM to $19 From $17, Maintains Overweight Rating MT
JPMorgan Raises Price Target on SLM to $18 From $16, Maintains Overweight Rating MT
Stephens Raises Price Target on SLM to $18 From $16, Maintains Equalweight Rating MT
Wedbush Raises SLM's PT to $21 From $18 After Investor Forum, Says Strategy Pivot to Balance Sheet Growth in 2025 Should Garner Higher Multiple; Keeps Outperform Rating MT
Wells Fargo Upgrades SLM to Overweight From Equalweight, Adjusts Price Target to $20 From $14 MT
Morgan Stanley Trims SLM's Price Target to $16 From $17, Keeps Overweight Rating MT
Wedbush Trims SLM's PT to $16 From $17 After Mixed Q3 Results, Delayed Loan Sale; Retains Outperform Rating MT
RBC Cuts Price Target on SLM Corp. to $16 From $19, Keeps Outperform Rating MT
Citigroup Cuts SLM's Price Target to $14 From $16, Keeps Neutral Rating MT
Morgan Stanley Trims SLM's Price Target to $17 From $18, Keeps Overweight Rating MT
Stephens Adjusts SLM's Price Target to $17 From $15, Keeps Equalweight Rating MT
RBC Lifts Price Target on SLM to $19 From $18, Maintains Outperform Rating MT
Compass Point Adjusts Price Target on SLM to $19 From $18, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on SLM to $18 From $15, Keeps Overweight Rating MT
Wedbush Raises SLM's PT to $18 From $14 After 'Strong' Quarter Led by 'Solid' Net Interest Margin Expansion; Keeps Outperform Rating MT
JPMorgan Upgrades SLM to Overweight From Neutral, Adjusts Price Target to $17 From $16 MT
Compass Point Upgrades SLM to Buy From Neutral, Price Target is $18 MT
ANALYST RECOMMENDATIONS : Mosaic, Inspire Medical, London Stock Exchange, ResMed, Whitbread... Our Logo
Morgan Stanley Upgrades SLM to Overweight From Underweight, Adjusts Price Target to $15 From $14 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
21.79 USD
Average target price
22.82 USD
Spread / Average Target
+4.72%
High Price Target
26 USD
Spread / Highest target
+19.32%
Low Price Target
20 USD
Spread / Lowest Target
-8.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering SLM Corporation

Morgan Stanley
RBC Capital Markets
Citigroup
Deutsche Bank Securities
JPMorgan Chase
Stephens Inc.
Wedbush
Wells Fargo Securities
Compass Point
BMO Capital
Credit Suisse
Barclays
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings